Danaher (DHR) Q3 2026 Earnings
How Did DHR Stock React to Q3 2026 Earnings?
Did DHR Beat Earnings? Q3 2026 Results
Yes. Danaher reported Q3 2026 earnings of $2.11 a share on Oct 20, 2026, beating the $1.92 consensus estimate by 10.0%. Revenue was $6.6B against a $6.6B estimate.
Danaher posted a strong third quarter, with adjusted diluted EPS of $2.11 beating the $1.92 consensus by 10.02%, marking the fourth consecutive quarter the life sciences and diagnostics giant has cleared Wall Street's earnings bar. Revenue of $6.55 billion rose 8.3% year over year, landing just a hair below the $6.56 billion estimate, a rounding-level miss that did little to cloud the broader picture. The primary engine behind the profit beat was operational leverage and Danaher Business System execution, amplified by 17.0% GAAP sales growth in Diagnostics, which included a meaningful contribution from the Masimo Corporation acquisition. Non-GAAP free cash flow climbed roughly 19.0% to $1.63 billion, underscoring the durability of the company's cash generation. Looking ahead, management raised full-year 2026 adjusted diluted EPS guidance to $8.57 to $8.62, up from $8.45 to $8.60, and guided Q4 core revenue growth of approximately 3.0%, as respiratory testing revenue is expected to create a roughly 150 basis point headwind against otherwise solid underlying demand trends.
- Acceleration in core revenue growth excluding respiratory revenue to 5.5% from 4.5% in Q2
- Diagnostics segment GAAP sales growth of 17.0% driven by Masimo acquisition (16.5% acquisition impact)
- Biotechnology core sales growth of 5.0%
- Life Sciences core sales growth of 4.5%
- DBS-driven execution driving double-digit adjusted EPS growth
- Operating cash flow grew approximately 13.5% year-over-year
- Free cash flow grew approximately 19.0% year-over-year
- Net discrete tax benefits of $263 million from release of reserves for uncertain tax positions
“We delivered better-than-expected third quarter revenue, earnings and cash flow, and are encouraged by the improving trends we saw across our end markets. The continued acceleration in core revenue growth excluding respiratory revenue, together with DBS-driven execution drove double-digit adjusted EPS growth and underscored our ability to convert improving demand into strong financial performance.”
Danaher CEO, on the earnings call
What Is Danaher's Outlook?
For Q4 2026, Danaher expects non-GAAP core revenue excluding respiratory revenue to increase 4.0%–5.0% year-over-year, with respiratory revenue creating an approximately 150 basis point headwind, resulting in core revenue growth of approximately 3.0%. Q4 adjusted operating profit margin is expected to be approximately 29.5%. For full year 2026, the company raised adjusted diluted net EPS guidance to $8.57–$8.62, up from previous guidance of $8.45–$8.60. By segment for Q4: Biotechnology core sales growth expected at mid-single digit, Life Sciences at 4.0%–5.0%, and Diagnostics up slightly. Full year core sales growth is expected at approximately 2.5%, with core sales excluding respiratory testing at mid-single digit. The full year effective tax rate is expected at approximately 17.0%.
DHR YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $6.6B | $6.1B | +8.3% |
| Gross Profit | $3.8B | $3.5B | +8.9% |
| Operating Income | $1.2B | $1.2B | +7.9% |
| Net Income | $1.2B | $908.0M | +32.9% |
DHR Revenue by Segment
When Does Danaher Report Next?
Figures from SEC filings and company reports. Not investment advice.